Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 69

Sort by

Sort Order Select

Journal Articles

Results from a Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Intermediate, or High Risk, Relapsed/Refractory Myelofibrosis

Blood (2019) 134 (Supplement_1): 558.

https://doi.org/10.1182/blood-2019-131217

Published: 2019

Journal Articles

Monotherapy Activity with the First CD20-Targeted Immunotoxin, MT-3724, in Subjects with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Paul A. Hamlin, MD, Vasile Musteata, MD PhD, Mamia Zodelava, MD, Steven I Park, MD, Christine Burnett, Kristina Dabovic, PharmD, Eric T Williams, PhD, Jack P Higgins, PhD, Daniel O. Persky, MD

Blood (2019) 134 (Supplement_1): 4098.

https://doi.org/10.1182/blood-2019-129243

Published: 2019

Journal Articles

Phase 2 Study of E7777, a Diphtheria Toxin Fragment-Interleukin-2 Fusion Protein, in Japanese Patients with Relapsed or Refractory Peripheral and Cutaneous T-Cell Lymphoma

Blood (2019) 134 (Supplement_1): 4032.

https://doi.org/10.1182/blood-2019-121723

Published: 2019

Journal Articles

Moxetumomab Pasudotox-Tdfk in Heavily Pretreated Patients with Relapsed/Refractory Hairy Cell Leukemia (HCL): Long-Term Follow-up from the Pivotal Phase 3 Trial

Robert J. Kreitman, MD, Claire E. Dearden, MD FRCP, FRCPath, Pier Luigi Luigi Zinzani, MD, Julio Delgado, Tadeusz Robak, MD, Philipp D le Coutre, MD, Bjorn T. Gjertsen, MD PhD, Xavier Troussard, MD, Gail J. Roboz, MD, Lionel Karlin, MD, Douglas E Gladstone, MD, Nataliya Kuptsova-Clarkson, MD, Shiyao Liu, Priti Patel, MD, Wyndham Wilson, MD, Ira Pastan, MD, Francis J. Giles, MD FRCPI, FRCPath

Blood (2019) 134 (Supplement_1): 2808.

https://doi.org/10.1182/blood-2019-122307

Published: 2019

Journal Articles

Early Response Observed in Pediatric Patients with Refractory/Relapsed B-Cell Non-Hodgkin Lymphoma Treated with Sequential Chimeric Antigen Receptor T Cells

Wenqun Zhang, MD, Bo Hu, MD, Ling Jing, MD, Jing Yang, MD, Shan Wang, MD, Yang Liu, MD, Juan Du, MD, Yaoliang Ren, MD, Yonghong Zhang, MD

Blood (2019) 134 (Supplement_1): 1945.

https://doi.org/10.1182/blood-2019-125753

Published: 2019

Journal Articles

Results of Pivotal Phase 2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Blood (2018) 132 (Supplement 1): 765.

https://doi.org/10.1182/blood-2018-99-118966

Published: 2018

Journal Articles

High Molecular Remission Rate in Pediatric Patients (pts) with Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (r/r ALL) Treated with Blinatumomab: Rialto an Open-Label, Multicenter, Expanded Access Study

Franco Locatelli, Gerhard Zugmaier, Peter Bader, MD PhD, Sima Jeha, MD, Paul-Gerhardt Schlegel, MD, Jean-Pierre Bourquin, MD PhD, Rupert Handgretinger, MD PhD, Benoit Brethon, Claudia Rossig, MD, Christiane Chen-Santel, MD

Blood (2018) 132 (Supplement 1): 1375.

https://doi.org/10.1182/blood-2018-99-109855

Published: 2018

Journal Articles

Evaluation of T Cell and Monocyte Immune Subsets in the Stem Cell Product of Patients Developing Engraftment Syndrome Following Autologous Stem Cell Transplantation for Multiple Myeloma and Lymphoma

Dante B. Descalzi-Montoya, PhD, Zheng Yang, MS, Kira Goldgirsh, MS, Rena Feinman, PhD, David S Siegel, MD PhD, Noa Biran, MD, David H. Vesole, MD PhD, Andre Goy, MD, Tatyana A. Feldman, MD, Lori A. Leslie, MD, Scott D. Rowley, MD, Alan P Skarbnik, MD, Phyllis McKiernan, Melissa Baker, MSN, ANP, Michele L. Donato, MD, Robert Korngold, PhD

Blood (2018) 132 (Supplement 1): 4604.

https://doi.org/10.1182/blood-2018-99-120103

Published: 2018

Journal Articles

Elevated IL-1Ra Levels in the Stem Cell Product Is Associated with the Development of Engraftment Syndrome Following Autologous Stem Cell Transplantation for the Treatment of Multiple Myeloma and Lymphoma

Stacey L. Fanning, PhD, Kira Goldgirsh, MS, Dante B. Descalzi-Montoya, PhD, Rena Feinman, PhD, David S Siegel, MD PhD, Noa Biran, MD, David H. Vesole, MD PhD, Andre Goy, MD, Tatyana A. Feldman, MD, Lori A. Leslie, MD, Scott D. Rowley, MD, Alan P Skarbnik, MD, Phyllis McKiernan, Melissa Baker, MSN, ANP, Michele L. Donato, MD, Robert Korngold, PhD

Blood (2018) 132 (Supplement 1): 2131.

https://doi.org/10.1182/blood-2018-99-118763

Published: 2018

Journal Articles

Results of Pivotal Phase 2 Trial of SL-401 in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Blood (2017) 130 (Supplement 1): 1298.

https://doi.org/10.1182/blood.V130.Suppl_1.1298.1298

Published: 2017

Journal Articles

Prolonged Remission Achieved in a Relapsing Idiopathic Multicentric Castleman Disease Patient with a Novel, Targeted Treatment Approach

David C Fajgenbaum, MDMBA,MSc, Dustin Shilling, PhD, Helen L Partridge, BS, Sheila K Pierson, MS, Jason R Ruth, PhD, Christopher Sheild Nabel, MD PhD, Katie Stone, BS, Vandana Chaturvedi, PhD, Michael B. Jordan, MD, Adam D. Cohen, MD, Vera Krymskaya, PhD, Arthur H Rubenstein, MBBCh, Frits van Rhee, MD PhD, Thomas S Uldrick, MDMS

Blood (2017) 130 (Supplement 1): 3593.

https://doi.org/10.1182/blood.V130.Suppl_1.3593.3593

Published: 2017

Journal Articles

Comparable Outcome of CD3+-/CD19+ Depleted Haploidentical with Matched Sibling Donor Hematopoietic Stem Cell Transplantation for Advanced Stage Sickle Cell Disease: Result of a Pilot Study

Selim Corbacioglu, MD PhD, Juergen Foell, MD, Daniel Wolff, MD, Ernst Holler, MD, Beatrix Pfirstinger, MD, Klaus Thorsten Rehe, MD, Petra Hoffmann, PhD, Matthias Edinger, MD, Anja Troeger, MD, Svatava Srutkova, MD

Blood (2017) 130 (Supplement 1): 4594.

https://doi.org/10.1182/blood.V130.Suppl_1.4594.4594

Published: 2017

Journal Articles

Results from Ongoing Phase 1/2 Trial of SL-401 As Consolidation Therapy in Patients with Acute Myeloid Leukemia (AML) in Remission with Minimal Residual Disease (MRD)

Blood (2017) 130 (Supplement 1): 2583.

https://doi.org/10.1182/blood.V130.Suppl_1.2583.2583

Published: 2017

Journal Articles

First-in-Human Clinical Trial of the IL-15 Super-Agonist Complex ALT-803 for Patients Relapsed after Allogeneic Hematopoietic Cell Transplantation

Rizwan Romee, MD, Sarah Cooley, MD, Melissa Berrien-Elliott, PhD, Peter Westervelt, MDPhD, Michael R Verneris, MD, John E. Wagner, MD, Daniel J. Weisdorf, MD, Bruce Blazar, MD, John F DiPersio, MD PhD, Amanda F. Cashen, MD, Emily K Jeng, Amy Rock, Hing C Wong, PhD, Todd A. Fehniger, MDPhD, Jeffrey S. Miller, MD

Blood (2017) 130 (Supplement 1): 274.

https://doi.org/10.1182/blood.V130.Suppl_1.274.274

Published: 2017

Journal Articles

Results from Ongoing Phase 1/2 Trial of SL-401 in Patients with Myeloproliferative Neoplasms Including Chronic Myelomonocytic Leukemia and Primary Myelofibrosis

Mrinal M. Patnaik, MDMBBS, Vikas Gupta, MD PhD, Gary J. Schiller, Sangmin Lee, MD, Abdulraheem Yacoub, MD, Haris Ali, MD, Moshe Talpaz, MD, Megan Sardone, Halyna Wysowskyj, Shay Shemesh, Janice Chen, PhD, Christopher Brooks, PhD, Trishna Goswami, MD, Animesh Pardanani, MBBS PhD, Ayalew Tefferi, MD, Srdan Verstovsek, MD PhD, Joseph David Khoury, MD, Naveen Pemmaraju, MD

Blood (2017) 130 (Supplement 1): 2908.

https://doi.org/10.1182/blood.V130.Suppl_1.2908.2908

Published: 2017

Journal Articles

Utility of D-Dimer LEVEL As a Marker for Differentiation Syndrome, Infection, and Death in ACUTE Promyelocytic Leukemia (APL)

Catherine R. Caprara, MSN, NP, Prachi Kharkhanis, Kathryn Sarah Simon, PA-C, Stephanie Debragga, Sheldon Bolds, Martha L. Arellano, MD, Anand Jillella, MD, Vamsi Kota, MBBS

Blood (2017) 130 (Supplement 1): 5071.

https://doi.org/10.1182/blood.V130.Suppl_1.5071.5071

Published: 2017

Journal Articles

Phase 1 study of the anti-CD22 immunotoxin moxetumomab pasudotox for childhood acute lymphoblastic leukemia

Alan S. Wayne, Nirali N. Shah, Deepa Bhojwani, Lewis B. Silverman, James A. Whitlock, Maryalice Stetler-Stevenson, Weili Sun, Meina Liang, Jie Yang, Robert J. Kreitman, Mark C. Lanasa, Ira Pastan

Blood (2017) 130 (14): 1620–1627.

https://doi.org/10.1182/blood-2017-02-749101

Published: 2017

Includes: Supplemental data

Journal Articles

Data from the First CD20-Targeted Immunotoxin, MT-3724, in a Phase I/Ib Study in Relapsed/Refractory (R/R) Non-Hodgkin's B-Cell Lymphoma (NHL)

Paul A Hamlin, Jr., MD, Michelle A. Fanale, MD, Steven I. Park, MD, David J. Valacer, MD, Jack Higgins, PhD, Anas Younes, MD

Blood (2016) 128 (22): 4200.

https://doi.org/10.1182/blood.V128.22.4200.4200

Published: 2016

Journal Articles

Results from Phase 2 Trial Ongoing Expansion Stage of SL-401 in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Naveen Pemmaraju, MD, Andrew A. Lane, MD PhD, Kendra L. Sweet, MD, Anthony S. Stein, MD, Sumithira Vasu, MBBS, William Blum, MD, David A Rizzieri, MD, Eunice S. Wang, MD, Madeleine Duvic, MD, Janice Chen, PhD, Shay Shemesh, MA, Peter McDonald, Christopher L. Brooks, PhD, Jeffrey E. Lancet, MD, Hagop M. Kantarjian, MD, Marina Konopleva, MD PhD

Blood (2016) 128 (22): 342.

https://doi.org/10.1182/blood.V128.22.342.342

Published: 2016

Journal Articles

Exome Sequencing of Hodgkin's and Non-Hodgkin Composite Lymphomas Identifies Shared Somatic Mutations Indicative of Common Founding Precursors

Felicia Gomez, PhD, Matthew Matlock, BA, Kilannin Krysiak, PhD, Yi-Shan Lee, MD, Eric J. Duncavage, MD, Michelle O'Laughlin, BS, Malachi Griffith, PhD, Todd A Fehniger, MD PhD, Lukas D. Wartman, MD, Obi L. Griffith, PhD

Blood (2016) 128 (22): 5285.

https://doi.org/10.1182/blood.V128.22.5285.5285

Published: 2016

NARROW

Results from a Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Intermediate, or High Risk, Relapsed/Refractory Myelofibrosis

Monotherapy Activity with the First CD20-Targeted Immunotoxin, MT-3724, in Subjects with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Phase 2 Study of E7777, a Diphtheria Toxin Fragment-Interleukin-2 Fusion Protein, in Japanese Patients with Relapsed or Refractory Peripheral and Cutaneous T-Cell Lymphoma

Moxetumomab Pasudotox-Tdfk in Heavily Pretreated Patients with Relapsed/Refractory Hairy Cell Leukemia (HCL): Long-Term Follow-up from the Pivotal Phase 3 Trial

Early Response Observed in Pediatric Patients with Refractory/Relapsed B-Cell Non-Hodgkin Lymphoma Treated with Sequential Chimeric Antigen Receptor T Cells

Results of Pivotal Phase 2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

High Molecular Remission Rate in Pediatric Patients (pts) with Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (r/r ALL) Treated with Blinatumomab: Rialto an Open-Label, Multicenter, Expanded Access Study

Evaluation of T Cell and Monocyte Immune Subsets in the Stem Cell Product of Patients Developing Engraftment Syndrome Following Autologous Stem Cell Transplantation for Multiple Myeloma and Lymphoma

Elevated IL-1Ra Levels in the Stem Cell Product Is Associated with the Development of Engraftment Syndrome Following Autologous Stem Cell Transplantation for the Treatment of Multiple Myeloma and Lymphoma

Results of Pivotal Phase 2 Trial of SL-401 in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Prolonged Remission Achieved in a Relapsing Idiopathic Multicentric Castleman Disease Patient with a Novel, Targeted Treatment Approach

Comparable Outcome of CD3+-/CD19+ Depleted Haploidentical with Matched Sibling Donor Hematopoietic Stem Cell Transplantation for Advanced Stage Sickle Cell Disease: Result of a Pilot Study

Results from Ongoing Phase 1/2 Trial of SL-401 As Consolidation Therapy in Patients with Acute Myeloid Leukemia (AML) in Remission with Minimal Residual Disease (MRD)

First-in-Human Clinical Trial of the IL-15 Super-Agonist Complex ALT-803 for Patients Relapsed after Allogeneic Hematopoietic Cell Transplantation

Results from Ongoing Phase 1/2 Trial of SL-401 in Patients with Myeloproliferative Neoplasms Including Chronic Myelomonocytic Leukemia and Primary Myelofibrosis

Utility of D-Dimer LEVEL As a Marker for Differentiation Syndrome, Infection, and Death in ACUTE Promyelocytic Leukemia (APL)

Phase 1 study of the anti-CD22 immunotoxin moxetumomab pasudotox for childhood acute lymphoblastic leukemia

Data from the First CD20-Targeted Immunotoxin, MT-3724, in a Phase I/Ib Study in Relapsed/Refractory (R/R) Non-Hodgkin's B-Cell Lymphoma (NHL)

Results from Phase 2 Trial Ongoing Expansion Stage of SL-401 in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Exome Sequencing of Hodgkin's and Non-Hodgkin Composite Lymphomas Identifies Shared Somatic Mutations Indicative of Common Founding Precursors

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only